1. CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218). (14th November 2022) Authors: Kizilbash, Sani; Piccioni, David; Sahebjam, Solmaz; Villano, John; Jaeckle, Kurt; Welch, Mary; Kong, Xiao-Tang; Holdhoff, Matthias; Lammers, Anita; Remick, Adam; Reid, Joel; Allred, Jacob; Port, John; Lanza, Ian; McBrayer, Samuel; Kunos, Charles; Shapiro, Geoffrey; Adjei, Alex Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗